Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 10 von 22
Cell, 2014-10, Vol.159 (3), p.676-690
2014

Details

Autor(en) / Beteiligte
Titel
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Ist Teil von
  • Cell, 2014-10, Vol.159 (3), p.676-690
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2014
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
  • Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver alterations to include EIF1AX, PPM1D, and CHEK2 and diverse gene fusions. These discoveries reduced the fraction of PTC cases with unknown oncogenic driver from 25% to 3.5%. Combined analyses of genomic variants, gene expression, and methylation demonstrated that different driver groups lead to different pathologies with distinct signaling and differentiation characteristics. Similarly, we identified distinct molecular subgroups of BRAF-mutant tumors, and multidimensional analyses highlighted a potential involvement of oncomiRs in less-differentiated subgroups. Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease. [Display omitted] •Expanded the somatic genetic landscape of papillary thyroid cancer•Identified new cancer genes and new driver events in known cancer genes.•Signaling signatures and differentiation properties characterized across cohort•Developed a molecular classification of papillary thyroid carcinoma A TCGA analysis of papillary thyroid carcinoma paints a nearly complete picture of its genomic drivers, reveals intriguing differences between the consequences of mutant BRAF and RAS signaling, and enables development of a scoring and classification scheme that may beneficially alter treatment courses.
Sprache
Englisch
Identifikatoren
ISSN: 0092-8674
eISSN: 1097-4172
DOI: 10.1016/j.cell.2014.09.050
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4243044

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX